Actuate Therapeutics Inc.
Organization details
- Legal name
- Actuate Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Fort Worth
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ACTU
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001652935
- EIN
- 47-3044785
Board of directors
-
Aaron G.l. Fletcher · DirectorSince 2024
-
Amy L. Ronneberg · DirectorSince 2024
-
Dan Zabrowski · DirectorSince 2024
-
Daniel M. Schmitt · Director · President, CEO and DirectorSince 2024
-
James T. Demetriades · DirectorSince 2026
-
Jason A. Keyes · DirectorSince 2024
-
Leslie W. Kreis · DirectorSince 2025
-
Martin H. Huber Jr. · DirectorSince 2026
-
Roger Sawhney · DirectorSince 2024
-
Todd S. Thomson · DirectorSince 2024
Chief executives
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.8%
-
99.8%
Board connections
5 of this board's directors also sit on 6 other boards. 5 are in the same sector.
-
Cognition Therapeutics Inc. Same sectorvia Aaron G.l. Fletcher and Leslie W. Kreis
-
Adlai Nortye Group Ltd. Same sectorvia Roger Sawhney
-
Arbutus Biopharma Corporation Same sectorvia Roger Sawhney
-
Cue Biopharma Inc. Same sectorvia Aaron G.l. Fletcher
-
Syndax Pharmaceuticals Inc. Same sectorvia Martin H. Huber Jr.
- via Todd S. Thomson
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $50,000
- 1 purchase by 1 insider
- Sold, last 12 months
- $1,624,000
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 28, 2026 | Daniel M. Schmitt Director, Officer (President, CEO and Director) | Open-market purchase | +140,844 | $0.36 | $50,000 |
| Aug 14, 2026 | Daniel M. Schmitt Director, Officer (President, CEO and Director) | Option exercise | +272,056 | — | — |
| Aug 14, 2026 | Daniel M. Schmitt Director, Officer (President, CEO and Director) | Shares withheld for tax | −120,521 | $1.01 | $121,726 |
| Feb 13, 2026 | Daniel M. Schmitt Director, Officer (President, CEO and Director) | Option exercise | +272,055 | — | — |
| Feb 13, 2026 | Daniel M. Schmitt Director, Officer (President, CEO and Director) | Shares withheld for tax | −121,874 | $4.33 | $527,714 |
| Jan 5, 2026 | Todd S. Thomson Director, 10% owner | Open-market sale | −280,000 | $5.80 | $1,624,000 |
| Jun 27, 2025 | Bios Equity COF, LP Director, 10% owner | Open-market purchase | +71,428 | $7.00 | $499,996 |
| Jun 27, 2025 | BIOS Fund II, LP Director, 10% owner | Open-market purchase | +71,428 | $7.00 | $499,996 |
| Jun 27, 2025 | BIOS Actuate Co-Invest I, LP Director, 10% owner | Open-market purchase | +71,428 | $7.00 | $499,996 |
| Aug 14, 2024 | Kairos-Actuate SPV, L.P. Director, 1.5% Owner | Derivative conversion | +1,058,318 | — | — |
| Aug 14, 2024 | BP Directors, LP Director, 10% owner | Derivative conversion | +884,427 | — | — |
| Aug 14, 2024 | BIOS Equity Partners III, LP Director, 10% owner | Derivative conversion | +884,427 | — | — |
| Aug 14, 2024 | BIOS Fund II QP, LP Director, 10% owner | Derivative conversion | +884,427 | — | — |
| Aug 14, 2024 | Kairos-Actuate SPV, L.P. Director, 1.5% Owner | Derivative conversion | +726,163 | — | — |
| Aug 14, 2024 | BP Directors, LP Director, 10% owner | Open-market purchase | +375,000 | $8.00 | $3,000,000 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Actuate Therapeutics Inc.
Who is the CEO of Actuate Therapeutics Inc.?
Daniel M. Schmitt has been Actuate Therapeutics Inc.'s President, CEO and Director since August 2024.
How many directors are on Actuate Therapeutics Inc.'s board?
Actuate Therapeutics Inc.'s board has 10 directors: Aaron G.l. Fletcher, Amy L. Ronneberg, Dan Zabrowski, Daniel M. Schmitt, James T. Demetriades, Jason A. Keyes, Leslie W. Kreis, Martin H. Huber Jr., Roger Sawhney and Todd S. Thomson.
Are Actuate Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Actuate Therapeutics Inc. insiders bought $50,000 of shares in 1 purchase and sold $1.6 million of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="actuate-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.